GlassScriptPhysician profile
Kevin Reeder
NPI 1982650867
$3,567.31
in general payments reported to CMS, 2019-2025
16 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $35.04 · 2021: $217 · 2022: $482 · 2023: $417 · 2024: $473 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401 · Entertainment: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.82 |
| Entertainment | $120.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,281.62 | 2023-2025 | Infuse, Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $441.66 | 2020-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $264.71 | 2019 | |
| Lombart Brothers, INC. | $238.74 | 2025 | Opd-III |
| Alcon Vision LLC | $214.29 | 2019-2025 | Precision7, Clareon |
| Coopervision INC. | $177.59 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $156.84 | 2024-2025 | Xdemvy |
| Rxsight INC | $146.90 | 2022 | |
| Apellis Pharmaceuticals, INC. | $121.87 | 2023 | |
| Biotissue Holdings INC. | $121.84 | 2022 | |
| Optos, INC. | $120.93 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $106.12 | 2025 | |
| Sight Sciences, INC. | $80.62 | 2022 | |
| Glaukos Corporation | $59.08 | 2023 | |
| Allergan, INC. | $18.65 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $15.85 | 2024 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Reeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.